Rosai-Dorfman Disease clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
open to all eligible people
This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.
at UCSF
Our lead scientists for Rosai-Dorfman Disease research studies include Rohini Jain.
Last updated: